Questcor (QCOR) Misses on Q2 Earnings, Beats on Revenues - Analyst Blog

By
A A A

Questcor Pharmaceuticals Inc. ( QCOR ) reported second quarter 2014 earnings per share of $1.71, up from the year-ago earnings of $1.25 per share. Excluding share- based compensation expense, one-time items and non-cash expenses, earnings stood at $1.85 per share.

Excluding share-based compensation expense, earnings came in at $1.76 per share. The Zacks Consensus Estimate was $1.93.


Questcor Pharmaceuticals, Inc - Earnings Surprise | FindTheBest

Second quarter 2014 revenues climbed 51% to $278.8 million, easily beating the Zacks Consensus Estimate of $264 million.

Quarter in Detail

Higher revenues were driven by increased use of H.P. Acthar Gel in patients suffering from rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis, polymyositis, nephrotic syndrome, multiple sclerosis exacerbations, infantile spasms and symptomatic sarcoidosis.

We note that Acthar, an injectable drug, has been approved by the U.S. Food and Drug Administration for as many as 19 indications. Questcor shipped 8,850 vials of Acthar during the second quarter of 2014, up 26.0% year over year.

In the reported quarter, Acthar's new paid prescriptions were about 2,775 to 2,800, up 23% from the year-ago quarter.

Research and development (R&D) expenses were $22.0 million in the reported quarter, up 79.8% year over year. General and administrative expenses came in at $26.8 million, up 104.5% and selling and marketing expenses were $57.0 million, up 49.8%.

Questcor is working to expand Acthar's label further for the indications of amyotrophic lateral sclerosis (ALS), diabetic nephropathy and acute respiratory distress syndrome (ARDS).

Acquisition by Mallinckrodt

In Apr 2014, Questcor agreed to merge with Mallinckrodt ( MNK ). As per the terms of the agreement, shareholders of Questcor will receive $30.00 per share in cash and 0.897 Mallinckrodt shares for each Questcor share held. Based on the closing price of Mallinckrodt on Jul 18, 2014, the total value comes to $6.3 billion. Mallinckrodt expects to complete the transaction in Aug 2014.

Post-merger, Mallinckrodt shareholders will own approximately 50.5% while former Questcor shareholders will own approximately 49.5% of the combined company's stock.

Questcor carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the healthcare sector include Salix Pharmaceuticals ( SLXP ) and Ironwood Pharmaceuticals ( IRWD ). While Salix Pharma carries a Zacks Rank #1 (Strong Buy), Irownood Pharma is a Zacks Rank #2 (Buy) stock.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

QUESTCOR PHARMA (QCOR): Free Stock Analysis Report

MALLINCKRODT PL (MNK): Free Stock Analysis Report

IRONWOOD PHARMA (IRWD): Free Stock Analysis Report

SALIX PHARM-LTD (SLXP): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Earnings , Stocks

Referenced Stocks: QCOR , MNK , IRWD , SLXP

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

85,117,424
  • $6.78 ▲ 11.88%
77,261,676
  • $17.53 ▲ 1.56%
61,066,548
  • $6.90 ▲ 2.99%
56,847,440
  • $112.65 ▲ 2.96%
52,788,366
  • $7.78 ▲ 1.83%
50,761,400
  • $25.14 ▲ 2.91%
47,781,237
  • $45.35 ▲ 10.18%
45,664,909
  • $7.17 ▲ 2.14%
As of 12/18/2014, 04:15 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com